Chen et al. (2011) conclude that the reduced VAChT expression could contribute to cholinergic deficit in AD and altered neurotransmitter transporters could contribute to the pathophysiology of AD; which are potential targets for therapy (Chen et al., 2011). This evidence concerns the gene SLC6A2 and Alzheimer disease.